Material Agreements

LM FUNDING AMERICA, INC. entered into Securities Purchase Agreement with institutional investors valued at aggregate gross proceeds of approximately $6.0 million (effective 2025-12-19).

“On December 19, 2025, LM Funding America, Inc. (the “Company”) and institutional investors (the “Purchasers”) entered into a securities purchase agreement (the “Securities Purchase Agreement”), pursuant to which the Company agreed to issue to the Purchasers, in a registered direct offering (the “RDO”), 1,822,535 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), pre-funded warrants to purchase 7,332,395 shares of Common Stock (the “Pre-Funded Warrants”) with an exercise price of $0.001 per share in lieu of Shares, and common warrants to purchase 9,154,930 shares of Common Stock (the “Common Warrants”) with an exercise price of $0.71.”

Laird Superfood, Inc. entered into Navitas Acquisition Agreement with Encore Consumer Capital Fund II, LP, The Ira and Joanna Haber Family Trust, Advantage Capital Agribusiness Partners, L.P., and Global Superfoods Corp., solely with respect to Section 12.16 valued at $38.5 million (effective 2025-12-21).

“On December 21, 2025, Laird Superfood, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Navitas Acquisition Agreement ”) by and among the Company, Encore Consumer Capital Fund II, LP (“ Encore ”), in its capacity as a Seller (defined below) and the Seller representative, The Ira and Joanna Haber Family Trust, Dated October 5, 2015 (the “ Haber Family Trust ”), Advantage Capital Agribusiness Partners, L.P. (“ Advantage Capital ,” together with Encore and the Haber Family Trust, the “ Sellers ”), and, solely with respect to Section 12.16 thereof, Global Superfoods Corp. (“ GSC ”), pursuant to which, following the receipt of the Company Stockholder Approval (defined below), the Company will acquire, directly or indirectly, (i) all of the issued and outstanding units of Navitas LLC (“ Navitas ”) from the Sellers and (ii) all of the issued and outstanding capital stock of GSC from Encore for a purchase price of $38.5 million in cash, subject to customary purchase p”

Moleculin Biotech, Inc. amended Warrant Amendment with holders of the Company’s Series E warrants, Series F warrants, and Series G warrants valued at $3.90 per share (effective 2025-12-21).

“On December 21, 2025, Moleculin Biotech, Inc. (the “Company”) entered into separate warrant amendment agreements (collectively, the “Warrant Amendment”) with the holders of the Company’s Series E warrants (the “Series E warrants”), Series F warrants (the “Series F warrants”), and Series G warrants (the “Series G warrants,” and collectively with the Series E warrants and Series F warrants, the “Warrants”).”

AIRWA INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Cash fee equal to 5.0% of aggregate gross proceeds of the Offering plus expense reimbursements (effective 2025-12-18).

“In connection with the Offering, the Company entered into a placement agency agreement (the " Placement Agency Agreement "), dated December 18, 2025, with A.G.P./Alliance Global Partners (the " Placement Agent ") pursuant to which the Company agreed to pay the Placement Agent a total cash fee equal to 5.0% of the aggregate gross proceeds of the Offering and to reimburse the Placement Agent for (i) up to $15,000 for non-accountable expenses and (ii) up to $55,000 for the out-of-pocket accountable legal expenses incurred by the Placement Agent in connection with the Offering.”

AIRWA INC. entered into Share Purchase Agreement with certain investors valued at 15,382,378 shares of Common Stock at $1.02 per share for approximately $15,690,030 gross proceeds (effective 2025-12-18).

“On December 18, 2025, AiRWA Inc. (the " Company ") entered into a share purchase agreement (the " Purchase Agreement ") with certain investors, pursuant to which the Company agreed to sell to such investors 15,382,378 shares (the " Shares ") of common stock of the Company, par value $0.001 per share (the " Common Stock "), at a purchase price of $1.02 per share of Common Stock (the " Offering ").”

Fulgent Genetics, Inc. entered into Asset Purchase Agreement with Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting, LLC valued at $43.0 million in cash (effective 2025-12-20).

“On December 20, 2025, Buyer entered into an Asset Purchase Agreement (the “APA”) with Bako Pathology LP (“Sellers’ Representative”), Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting, LLC (collectively with Sellers’ Representative, the “Sellers”), and Fulgent Therapeutics, LLC (solely for purposes of Section 11.16 (and Article XI as it relates to Section 11.16) of the APA), pursuant to which Sellers, among other things, agreed to sell and Buyer agreed to purchase and assume, substantially all of the assets and certain specified liabilities related to Sellers’ business in dermatopathology and podiatric pathology and molecular diagnostic services and therapeutic products, for a base purchase price of $43.0 million in cash, subject to certain customary price adjustments.”

Fulgent Genetics, Inc. entered into Purchase and Sale Agreement with Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp. valued at $12.5 million in cash (effective 2025-12-20).

“On December 20, 2025, Inform Diagnostics, Inc. (the “Buyer”), a wholly owned subsidiary of Fulgent Genetics, Inc. (the “Company”), entered into a Purchase and Sale Agreement (the “PSA”) with Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp. (the “Seller”), Dermatopathology Experts, LLC (the “Target”), and Fulgent Therapeutics, LLC (solely for purposes of Section 11.16 (and Article XI as it relates to Section 11.16) of the PSA), pursuant to which Seller, among other things, agreed to sell and Buyer agreed to purchase, all of the issued and outstanding equity interests of the Target, for a base purchase price of $12.5 million in cash, subject to certain customary price adjustments.”

Blue Owl Technology Finance Corp. amended Collateral Management Agreement with Blue Owl Technology Credit Advisors LLC (effective 2025-12-16).

“OTCA will serve as collateral manager for the Issuer under an amended and restated collateral management agreement dated as of the Refinancing Date (the “Collateral Management Agreement”).”

Blue Owl Technology Finance Corp. amended OTF Loan Sale Agreement with Issuer (effective 2025-12-16).

“As part of the CLO Refinancing, the Company and the Issuer entered into an amended and restated loan sale agreement dated as of the Refinancing Date (the “OTF Loan Sale Agreement”), which provides for the sale and contribution of approximately $217.963 million funded par amount of middle market loans from the Company to the Issuer on the Refinancing Date and for future sales from the Company to the Issuer on an ongoing basis.”

Blue Owl Technology Finance Corp. amended Indenture with State Street Bank and Trust Company (effective 2025-12-16).

“The CLO Refinancing was executed by (A) the issuance of the following classes of notes and preferred shares pursuant to an indenture and security agreement dated as of December 13, 2023 (the “Original Closing Date”), as amended and supplemented by the first supplemental indenture dated as of the Refinancing Date (the “Indenture”), by and among the Issuer and State Street Bank and Trust Company”

Blue Owl Technology Finance Corp. entered into Class A-LR Credit Agreement with financial institution (effective 2025-12-16).

“The Class A-LR Loans were borrowed under a credit agreement (the “Class A-LR Credit Agreement”), dated as of the Refinancing Date, by and among the Issuer, as borrower, a financial institution, as lender, and State Street Bank and Trust Company, as collateral trustee and loan agent.”

Blue Owl Technology Finance Corp. amended Secured Credit Facility with Goldman Sachs Bank USA valued at Amendment No. 3 extended Reinvestment Period to November 16, 2028 and Scheduled Maturity Date to Nov (effective 2025-12-17).

“On December 17, 2025 (the “Amendment Date”), ORTF Funding I LLC (“ORTF Funding I”), a subsidiary of Blue Owl Technology Finance Corp. (the “Company”), entered into Amendment No. 3 (the “Amendment No. 3” and the facility as amended, the “Secured Credit Facility”), which amended (a) that certain Credit Agreement, dated as of November 16, 2021, as amended by Amendment No. 1 to the Credit Agreement, dated June 23, 2023, and Amendment No. 2, dated October 30, 2024, by and among ORTF Funding I, as borrower, the lenders from time to time parties thereto, Goldman Sachs Bank USA as Sole Lead Arranger, Syndication Agent and Administrative Agent and State Street Bank and Trust Company as Collateral Administrator, Collateral Agent and Collateral Custodian and (b) that certain Margining Agreement, dated as of November 16, 2021, as amended by Amendment No. 2, dated October 30, 2024 between ORTF Funding I, as borrower, and Goldman Sachs Bank USA, as administrative agent and calculation agent.”

Vireo Growth Inc. entered into APA with PharmaCann Inc., certain of PharmaCann's subsidiaries, and Argent Institutional Trust Company valued at $49,000,000.00 (effective 2025-12-16).

“On December 16, 2025, Vireo Health, Inc. (“ Buyer ”), a Delaware corporation and wholly owned subsidiary of Vireo Growth Inc. (the “ Company ”), the Company, PharmaCann Inc., a Delaware corporation (“ PharmaCann ”), certain of PharmaCann’s subsidiaries (collectively, with PharmaCann the “ Seller Parties ”), and Argent Institutional Trust Company (“ Agent ”), as collateral agent under the Indenture, dated as of June 24, 2021, by and among PharmaCann, as issuer, the Guarantors (as defined thereunder) party thereto, including the Seller Parties, and Agent, as trustee and collateral agent thereunder, entered into an Asset Purchase Agreement (the “ APA ”).”

Rocket Companies, Inc. amended Amended and Restated Master Repurchase Agreement with Bank of America, N.A. valued at Total funding capacity of $25.9 billion under all master repurchase agreements, early funding facili (effective 2025-12-19).

“On December 19, 2025, Rocket Mortgage, LLC (the "Company"), a Michigan limited liability company and indirect subsidiary of Rocket Companies, Inc. ("Rocket"), entered as a "guarantor" into that certain Amendment No. 9 (the "MRA Amendment") to that certain Amended and Restated Master Repurchase Agreement dated as of June 29, 2021 (the "Master Repurchase Agreement"), and the related Transaction Terms Letter, along with RCKT Mortgage SPE-A, LLC, as "seller", and Bank of America, N.A., as "buyer" as the other parties to the MRA Amendment and the Master Repurchase Agreement.”

Stone Point Credit Corp amended Second Amendment with the holders of the 2024 Notes (effective 2025-12-19).

“On December 19, 2025, the Company entered into that certain Second Amendment to Note Purchase Agreement (the "Second Amendment") by and among the Company and the holders of the 2024 Notes (as defined below), which amends that certain Note Purchase Agreement, dated as of September 17, 2024 with respect to the issuance and sale of $200,000,000 aggregate principal amount of the Company's Senior Notes (the "2024 Notes") due September 15, 2029 (as amended from time to time and as further amended by the Second Amendment, the "2024 Note Purchase Agreement").”

Stone Point Credit Corp amended First Amendment with the holders of the Notes (effective 2025-12-19).

“On December 19, 2025, the Company entered into that certain First Amendment to Note Purchase Agreement (the "First Amendment") by and among the Company and the holders of the Notes (as defined below), which amends that certain Note Purchase Agreement, dated as of March 21, 2025 with respect to the issuance and sale of (i) $60,000,000 6.03% Senior Notes, Series A, due May 15, 2028 and (ii) $240,000,000 6.26% Senior Notes, Series B, due May 15, 2030 (together, the "Notes") (as amended by the First Amendment, the "2025 Note Purchase Agreement").”

Stone Point Credit Corp amended Fifth Amendment with Capital One, National Association (effective 2025-12-16).

“On December 16, 2025, Stone Point Credit Corporation (the "Company") executed a letter agreement (the "Fifth Amendment") to amend its revolving credit agreement (as amended, the "Revolving Credit Agreement"), by and among, inter alios, the Company as the borrower, the lenders from time to time party thereto and Capital One, National Association, as the administrative agent, sole lead arranger and a lender.”

Apollo Debt Solutions BDC entered into Revolving Credit and Security Agreement with Toucan Funding LLC valued at $600 million (effective 2025-12-19).

“On December 19, 2025 (the “Closing Date”), Toucan Funding LLC (“Toucan Funding”), a Delaware limited liability company and newly formed subsidiary of Apollo Debt Solutions BDC, a Delaware statutory trust (the “Fund” or “us”), entered into a Revolving Credit and Security Agreement (the “Toucan Funding Credit Agreement”), with Toucan Funding, as borrower, the Fund, in its capacity as collateral manager, the lenders from time to time parties thereto, Truist Bank, as administrative agent and swingline lender, Truist Securities, Inc., as lead arranger, Citibank, N.A., as collateral agent, document custodian and custodian, and Virtus Group, LP, as collateral administrator.”

reAlpha Tech Corp. entered into Agreement and Plan of Merger with InstaMortgage Inc., reAlpha Merger Sub I, Inc., Shashank Shekhar and Ankur Dhingra valued at $8,500,000 (effective 2025-12-19).

“On December 19, 2025, reAlpha Tech Corp. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with InstaMortgage Inc., a California corporation (“InstaMortgage”), reAlpha Merger Sub I, Inc., a Delaware corporation and a newly formed wholly-owned subsidiary of the Company (the “Merger Sub”) and Shashank Shekhar (“Shekhar”) and Ankur Dhingra (“Dhingra” and together with Shekhar, the “Stockholders” and each a “Stockholder”).”

Clearwater Analytics Holdings, Inc. entered into Agreement and Plan of Merger with GT Silver BidCo, Inc. and GT Silver Merger Sub, Inc. (effective 2025-12-20).

“On December 20, 2025, Clearwater Analytics Holdings, Inc., a Delaware corporation, (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with GT Silver BidCo, Inc., a Delaware corporation (“ Parent ”), and GT Silver Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ Merger Sub ”)”

Alaska Silver Corp. amended Eighth Amendment to Promissory Note with Joe Piekenbrock valued at Interest rate changed from 5% per annum to 3.5% per annum; maturity extended from December 1, 2026 t (effective 2025-11-01).

“On December 17, 2025, WACG entered into the Eighth Amendment to Promissory Note (the "Amendment") with the Holder, pursuant to which, effective November 1, 2025, (a) interest on the outstanding principal balance of the Promissory Note accrues at a rate equal 3.5% per annum and (b) payments are to be made as follows: (i) monthly payments of $10,000 on the outstanding principal balance; (ii) in the event that the Company closes a financing round, a principal reduction payment equal to 6% of such financing round to be applied against the outstanding principal balance of the Promissory Note; (iii) payment of the remaining outstanding principal balance of the Promissory Note, together with all accrued interest, on July 1, 2027.”

Signing Day Sports, Inc. amended Amendment No. 2 to the Business Combination Agreement with One Blockchain LLC valued at Amended Business Combination Agreement among Signing Day Sports, BlockchAIn Digital Infrastructure, (effective 2025-12-21).

“On December 21, 2025, Signing Day Sports, Inc., a Delaware corporation (the “Company” or “Signing Day Sports”), entered into the Amendment No. 2 to the Business Combination Agreement (the “Amendment”) with One Blockchain LLC, a Delaware limited liability company (“One Blockchain”), BlockchAIn Digital Infrastructure, Inc., a Delaware corporation (“BlockchAIn”), BCDI Merger Sub I Inc., a Delaware corporation and a wholly owned subsidiary of BlockchAIn (“Merger Sub I”), and BCDI Merger Sub II LLC, a Delaware limited liability company and a wholly owned subsidiary of BlockchAIn (“Merger Sub II”).”

Nuveen Churchill Private Capital Income Fund amended Credit Agreement (as amended by Amendment No. 6) with Bank of America, N.A., as administrative agent, and the lenders party thereto (effective 2025-12-19).

“On December 19, 2025 (the “Amendment Date”), NCPCIF SPV II, LLC (“SPV II”), a wholly owned subsidiary of Nuveen Churchill Private Capital Income Fund (the “Fund”), entered into Amendment No. 6 to the Credit Agreement (the “Amendment”), amending the Credit Agreement, dated as of April 19, 2022 (as previously amended from time to time, and as further amended by the Amendment, the “Credit Agreement”), by and among SPV II, as the borrower, the co-borrowers party thereto, the lenders party thereto, Bank of America, N.A., as administrative agent, the Fund, as servicer, U.S. Bank Trust Company, National Association, as collateral administrator, and U.S. Bank National Association, as collateral custodian, relating to the revolving credit facility thereunder (the “Facility”).”

ARES STRATEGIC INCOME FUND entered into January 2039 CLO Credit Agreement with U.S. Bank Trust Company, National Association valued at $50.0 million (effective 2025-12-18).

“ADL CLO 8 incurred $50.0 million of Class A-1A Loans that mature on January 20, 2039 (the “January 2039 CLO Secured Loans”), under a Class A-1A Credit Agreement (the “January 2039 CLO Credit Agreement”), dated as of the Closing Date, by and among ADL CLO 8, as borrower, the lender party thereto, and U.S. Bank Trust Company, National Association (“U.S. Bank”), as loan agent and collateral trustee.”

Goldman Sachs Private Credit Corp. amended Sixth Amendment with Truist Bank valued at $3,275,000,000 (effective 2025-12-17).

“On December 17, 2025, Goldman Sachs Private Credit Corp. (the “Company”) entered into a sixth amendment (the “Sixth Amendment”) to the Senior Secured Revolving Credit Agreement, dated as of April 6, 2023 (as amended by the First Amendment to Senior Secured Revolving Credit Agreement, dated August 9, 2023, the Second Amendment to Senior Secured Revolving Credit Agreement, dated November 17, 2023, the Third Amendment to Senior Secured Revolving Credit Agreement, dated May 23, 2024, the Fourth Amendment to Senior Secured Revolving Credit Agreement, dated June 16, 2025, and the Fifth Amendment to Senior Secured Revolving Credit Agreement, dated October 14, 2025, as otherwise amended or modified, the “Truist Revolving Credit Facility”), by and among the Company, as borrower, the lenders and issuing banks party thereto, and Truist Bank, as administrative agent.”

Stepstone Private Credit Fund LLC entered into 2025 Note Purchase Agreement with qualified institutional investors valued at $75,000,000 (effective 2025-12-17).

“On December 17, 2025, StepStone Private Credit Fund LLC (the “ Company ”) entered into a Master Note Purchase Agreement (the “ 2025 Note Purchase Agreement ”) governing the issuance of $75,000,000 in aggregate principal amount of its 5.94% Series 2025 Senior Notes, Tranche A, due December 17, 2028”

Aether Holdings, Inc. entered into Purchase Agreement with 537 Greenwich Owner, LLC valued at $1,080,000.00 (effective 2025-07-21).

“On July 21, 2025, Aether Holdings, Inc. (the "Company") entered into a certain Purchase and Sale Agreement dated July 21, 2025 (the "Purchase Agreement") with 537 Greenwich Owner, LLC (the "Seller"), pursuant to which the Company agreed to purchase from the Seller the retail level office space located at 110 Charlton Street, Unit RET B, New York, NY 10014 (the "Property").”

Medline Inc. entered into Information and Access Agreement with Company and entities affiliated with Hux Investment Pte. Ltd valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Information and Access Agreement, dated December 16, 2025, by and among the Company and entities affiliated with Hux Investment Pte. Ltd (the “ Information and Access Agreement ”).”

Medline Inc. entered into Director Nomination Agreement - Mills Family with Company and entities affiliated with the Mills Family valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Director Nomination Agreement, dated December 16, 2025, by and among the Company and entities affiliated with the Mills Family (the “ Mills Family Director Nomination Agreement ”);”

Medline Inc. entered into Director Nomination Agreement - H&F with Company and entities affiliated with Hellman & Friedman LLC valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Director Nomination Agreement, dated December 16, 2025, by and among the Company and entities affiliated with Hellman & Friedman LLC (the “ H&F Director Nomination Agreement ”);”

Medline Inc. entered into Director Nomination Agreement - Carlyle with Company and entities affiliated with The Carlyle Group Inc. valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Director Nomination Agreement, dated December 16, 2025, by and among the Company and entities affiliated with The Carlyle Group Inc. (the “ Carlyle Director Nomination Agreement ”);”

Medline Inc. entered into Director Nomination Agreement - Blackstone with Company and entities affiliated with Blackstone Inc. valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Director Nomination Agreement, dated December 16, 2025, by and among the Company and entities affiliated with Blackstone Inc. (the “ Blackstone Director Nomination Agreement ”);”

Medline Inc. entered into Registration Rights Agreement with Company and other persons valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Registration Rights Agreement, dated December 16, 2025, by and among the Company and each of the other persons from time to time party thereto (the “ Registration Rights Agreement ”);”

Medline Inc. entered into Exchange Agreement with Company, Medline Holdings and holders of common units valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Exchange Agreement, dated December 16, 2025, by and among the Company, Medline Holdings and holders of common units of Medline Holdings (“ Common Units ”) from time to time party thereto (the “ Exchange Agreement ”);”

Medline Inc. entered into Tax Receivable Agreement with Company and other persons valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Tax Receivable Agreement, dated December 16, 2025, by and among the Company and each of the other persons from time to time party thereto (the “ Tax Receivable Agreement ”);”

Medline Inc. entered into Second Amended and Restated Limited Partnership Agreement of Medline Holdings, LP with Medline Holdings, LP and other parties valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“Item 1.01 Entry into a Material Definitive Agreement. In connection with the initial public offering (the “ Offering ” or the “ IPO ”) by Medline Inc. (the “ Company ”) of its Class A common stock, par value $0.0001 per share (the “ Class A Common Stock ”), described in the prospectus (the “ Prospectus ”), dated December 16, 2025, filed with the Securities and Exchange Commission pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the “ Securities Act ”), which is deemed to be part of the Registration Statement on Form S-1 (File No. 333-291112) (as amended, the “ Registration Statement ”), the following agreements were entered into: • the Second Amended and Restated Limited Partnership Agreement of Medline Holdings, LP (“ Medline Holdings ”), dated December 16, 2025, by and among the Company and the other parties thereto (the “ Medline Holdings Limited Partnership Agreement ”);”

Andersen Group Inc. entered into HO Promissory Note with Andersen Aggregator LLC (effective 2025-12-16).

“”), the following agreements were entered into, which were previously filed as exhibits to the Registration Statement: • the Limited Liability Company Agreement of AT Umbrella LLC, dated as of December 16, 2025, by and among the Company, AT Umbrella LLC, and Andersen Aggregator LLC, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein; • the Managing Director Matters Agreement, dated as of December 16, 2025, by and between the Company and Andersen Aggregator LLC, which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein; • the Tax Receivable Agreement, dated as of December 16, 2025, by and between the Company and Andersen Aggregator LLC, which is filed as Exhibit 10.3 to this Current Report on Form 8-K and is incorporated by reference herein; • CA Promissory Notes, each dated as of Decem”

Andersen Group Inc. entered into CA Promissory Notes with Andersen Aggregator LLC (effective 2025-12-16).

“”), the following agreements were entered into, which were previously filed as exhibits to the Registration Statement: • the Limited Liability Company Agreement of AT Umbrella LLC, dated as of December 16, 2025, by and among the Company, AT Umbrella LLC, and Andersen Aggregator LLC, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein; • the Managing Director Matters Agreement, dated as of December 16, 2025, by and between the Company and Andersen Aggregator LLC, which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein; • the Tax Receivable Agreement, dated as of December 16, 2025, by and between the Company and Andersen Aggregator LLC, which is filed as Exhibit 10.3 to this Current Report on Form 8-K and is incorporated by reference herein; • CA Promissory Notes, each dated as of Decem”

Andersen Group Inc. entered into Tax Receivable Agreement with Andersen Aggregator LLC (effective 2025-12-16).

“”), the following agreements were entered into, which were previously filed as exhibits to the Registration Statement: • the Limited Liability Company Agreement of AT Umbrella LLC, dated as of December 16, 2025, by and among the Company, AT Umbrella LLC, and Andersen Aggregator LLC, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein; • the Managing Director Matters Agreement, dated as of December 16, 2025, by and between the Company and Andersen Aggregator LLC, which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein; • the Tax Receivable Agreement, dated as of December 16, 2025, by and between the Company and Andersen Aggregator LLC, which is filed as Exhibit 10.3 to this Current Report on Form 8-K and is incorporated by reference herein; • CA Promissory Notes, each dated as of Decem”

Andersen Group Inc. entered into Managing Director Matters Agreement with Andersen Aggregator LLC (effective 2025-12-16).

“the Managing Director Matters Agreement, dated as of December 16, 2025, by and between the Company and Andersen Aggregator LLC”

Andersen Group Inc. entered into Limited Liability Company Agreement of AT Umbrella LLC with Andersen Aggregator LLC (effective 2025-12-16).

“the Limited Liability Company Agreement of AT Umbrella LLC, dated as of December 16, 2025, by and among the Company, AT Umbrella LLC, and Andersen Aggregator LLC”

SharonAI Holdings Inc. entered into Convertible Note Agreement with certain investors (the "Noteholders") valued at approximately US$ 100,000,000 (effective 2025-12-19).

“On December 19, 2025, SharonAI, Inc. (“SharonAI Inc.”) and SharonAI Pty Ltd (“SharonAI Pty Ltd”), each a subsidiary of SharonAI Holdings Inc. (“SharonAI”), entered into a Convertible Note Agreement (the “Agreement”) with certain investors (the “Noteholders”), pursuant to which the Noteholders agreed to provide financing in the aggregate principal amount of approximately US$ 100,000,000 of unsecured, redeemable, convertible notes (the “Notes”).”

SharonAI Holdings Inc. amended YA Amendment with YA II PN, Ltd valued at $350,000 initial payment, plus final payment equal to outstanding principal, Redemption Premium, acc (effective 2025-12-15).

“On December 15, 2025, SharonAI entered into an Amendment (the “ YA Amendment ”) to Convertible Promissory Notes and Note Purchase Agreement (the “ YA Agreements ”) with YA II PN, Ltd (“ YA ”).”

American Drive Acquisition Co entered into Administrative Services Agreement with Petit Monts LLC valued at Administrative services agreement with sponsor (effective 2025-12-17).

“· An Administrative Services Agreement, dated December 17, 2025, between the Company and the Sponsor, a copy of which is filed as Exhibit 10.6 to this Report and incorporated herein by reference.”

American Drive Acquisition Co entered into Letter Agreement with Company, its officers, its directors and the Sponsor valued at Letter agreement regarding insider arrangements (effective 2025-12-17).

“· A Letter Agreement, dated December 17, 2025 (the “ Letter Agreement ”), by and among the Company, its officers, its directors and the Sponsor, a copy of which is attached as Exhibit 10.5 hereto and incorporated herein by reference.”

American Drive Acquisition Co entered into Cantor Private Placement Warrants Purchase Agreement with Cantor Fitzgerald & Co. valued at Private placement of warrants to underwriter (effective 2025-12-17).

“· A Private Placement Warrants Purchase Agreement, dated December 17, 2025 (the “ Cantor Private Placement Warrants Purchase Agreement ”), by and between the Company and Representative, a copy of which is attached as Exhibit 10.4 hereto and incorporated herein by reference.”

American Drive Acquisition Co entered into Sponsor Private Placement Warrants Purchase Agreement with Petit Monts LLC valued at Private placement of warrants to sponsor (effective 2025-12-17).

“· A Private Placement Warrants Purchase Agreement, dated December 17, 2025 (the “ Sponsor Private Placement Warrants Purchase Agreement ”), by and between the Company and Petit Monts LLC, a Delaware limited liability company (the “ Sponsor ”), a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.”

American Drive Acquisition Co entered into Registration Rights Agreement with certain security holders valued at Registration rights agreement (effective 2025-12-17).

“· A Registration Rights Agreement, dated December 17, 2025, by and among the Company and certain security holders, a copy of which is attached as Exhibit 10.2 hereto and incorporated herein by reference.”

American Drive Acquisition Co entered into Investment Management Trust Agreement with Continental Stock Transfer & Trust Company valued at Trust agreement for IPO proceeds (effective 2025-12-17).

“· An Investment Management Trust Agreement, dated December 17, 2025, by and between the Company and Continental Stock Transfer & Trust Company, as trustee, a copy of which is attached as Exhibit 10.1 hereto and incorporated herein by reference.”

American Drive Acquisition Co entered into Warrant Agreement with Continental Stock Transfer & Trust Company valued at Warrant agreement for warrants forming part of the units (effective 2025-12-17).

“· A Warrant Agreement, dated December 17, 2025, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent, a copy of which is attached as Exhibit 4.1 hereto and incorporated herein by reference.”